TY - JOUR
T1 - Body composition and quality of life in adults treated with GH therapy
T2 - A systematic review and meta-analysis
AU - Hazem, Ahmad
AU - Elamin, Mohamed B.
AU - Bancos, Irina
AU - Malaga, German
AU - Prutsky, Gabriela
AU - Domecq, Juan Pablo
AU - Elraiyah, Tarig A.
AU - Abu Elnour, Nisrin O.
AU - Prevost, Yolanda
AU - PAlmandoz, Jaime
AU - Zeballos-Palacios, Claudia
AU - Velasquez, Edgar R.
AU - Erwin, Patricia J.
AU - Natt, Neena
AU - Montori, Victor M.
AU - Murad, Mohammad Hassan
PY - 2012/1
Y1 - 2012/1
N2 - Objective: To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition. Data sources: We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus throughApril 2011.We also reviewed reference lists and contacted experts to identify candidate studies. Study selection:Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo. Data synthesis: We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the I 2 statistic. Results: Fifty-four RCTswere included enrolling over 3400 patients. The quality of the included trialswas fair. GH use was associated with statistically significant reduction in weight (WMD, 95% confidence interval (95% CI): K2.31 kg, K2.66 and K1.96) and body fat content (WMD, 95% CI: K2.56 kg, K2.97 andK2.16); increase in lean body mass(WMD,95%CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95% CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95% CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible. Results: GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.
AB - Objective: To summarise the evidence about the efficacy and safety of using GH in adults with GH deficiency focusing on quality of life and body composition. Data sources: We searched MEDLINE, EMBASE, Cochrane CENTRAL, Web of Science and Scopus throughApril 2011.We also reviewed reference lists and contacted experts to identify candidate studies. Study selection:Reviewers, working independently and in duplicate, selected randomised controlled trials (RCTs) that compared GH to placebo. Data synthesis: We pooled the relative risk (RR) and weighted mean difference (WMD) by the random effects model and assessed heterogeneity using the I 2 statistic. Results: Fifty-four RCTswere included enrolling over 3400 patients. The quality of the included trialswas fair. GH use was associated with statistically significant reduction in weight (WMD, 95% confidence interval (95% CI): K2.31 kg, K2.66 and K1.96) and body fat content (WMD, 95% CI: K2.56 kg, K2.97 andK2.16); increase in lean body mass(WMD,95%CI: 1.38, 1.10 and 1.65), the risk of oedema (RR, 95% CI: 6.07, 4.34 and 8.48) and joint stiffness (RR, 95% CI: 4.17, 1.4 and 12.38); without significant changes in body mass index, bone mineral density or other adverse effects. Quality of life measures improved in 11 of the 16 trials although meta-analysis was not feasible. Results: GH therapy in adults with confirmed GH deficiency reduces weight and body fat, increases lean body mass and increases oedema and joint stiffness. Most trials demonstrated improvement in quality of life measures.
UR - https://www.scopus.com/pages/publications/84055199671
U2 - 10.1530/EJE-11-0558
DO - 10.1530/EJE-11-0558
M3 - Artículo de revisión
C2 - 21865409
AN - SCOPUS:84055199671
SN - 0804-4643
VL - 166
SP - 13
EP - 20
JO - European Journal of Endocrinology
JF - European Journal of Endocrinology
IS - 1
ER -